Trials / Completed
CompletedNCT03283696
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaratumab | Administered IV |
| DRUG | Doxorubicin | Administered IV |
| DRUG | Ifosfamide | Administered IV |
| DRUG | Mesna | Administered per standard of care |
Timeline
- Start date
- 2017-10-18
- Primary completion
- 2019-04-29
- Completion
- 2019-08-25
- First posted
- 2017-09-14
- Last updated
- 2020-09-10
- Results posted
- 2020-09-10
Locations
6 sites across 3 countries: United States, Germany, Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03283696. Inclusion in this directory is not an endorsement.